Abstract:Abstract Breast Cancer is the most common cancer diagnosed in women in the United States. Second only to lung cancer, breast cancer results in the greatest number of cancer deaths for women. Hormone receptor positive (HR+) breast cancers - cancers expressing the nuclear receptors for steroid hormones estrogen and progesterone, termed the estrogen receptor (ER) and progesterone receptor (PR) - make up the largest proportion of diagnosed breast cancers by a significant margin. So, although the HR+ subtype is less aggressive compared to others, it continues to be the largest contributor to breast cancer mortality. Treatment consists of anti-endocrine therapies, largely targeting ER/estrogen, the established drivers of breast cancer growth. Most women respond well to these therapies, but for women who do not, there are few alternative options. With the advent of immunotherapy and its successes in treating and controlling certain tumor types, many were hopeful that it could be employed for breast cancer as well. However, breast cancers, especially HR+ breast cancers, are considered “immune cold.” They lack high proportions of tumor-infiltrating lymphocytes (TILs), have low neoantigen production, and high percentages of immunosuppressive cells. A contributing factor could be the hormones present in the tumor microenvironment. The accepted paradigm is that lifetime exposure to estrogens drives the development of HR+ breast cancer, but both estrogen and progesterone are part of the normal menstrual cycle. Prior work from our lab has uncovered a novel immune-modulatory role for progesterone, pivotal to promoting the growth of PR-positive mammary tumors. Recent preliminary data from our lab show that progesterone treatment conveys immune protection against T cell killing in a co-culture with E0771 mammary gland tumor cells. However, when activated in monoculture, T cells exposed to increasing concentrations of progesterone have no differing expression of cell surface activation or exhaustion markers, implying that progesterone is not eliciting this effect by interfering with the T cell activation cascade nor is it inducing premature exhaustion. Interestingly, progesterone treatment instead leads to a concentration-dependent increase in T cell death compared to the untreated control. In vivo, these results are supported as progesterone treatment decreases the amount of total CD3+ T cells, and specifically the cytotoxic CD8+ subset, in the mammary glands of mice. These results suggest that progesterone could modulate the breast and tumor microenvironment, providing tumor cells with protection from immunosurveillance and contributing to HR+ breast cancer development. These data also argue for the use of anti-progestins to be added to the HR+ breast cancer treatment regimen to boost anti-tumor immune activity. Citation Format: Amanda Heard, Lauryn R. Werner, Eilidh I. Chowanec, Harmony Saunders, Julio Tinoco, Zachary C. Hartman, Christy R. Hagan. Progesterone promotes immunosuppression in the murine mammary gland by causing T cell death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6877.

Progesterone Impairs Antigen-Non-specific Immune Protection by CD8 T Memory Cells Via Interferon-Γ Gene Hypermethylation

Progesterone inhibits Toll-like receptor 4-mediated innate immune response in macrophages by suppressing NF-κB activation and enhancing SOCS1 expression

miR-155 mediates suppressive effect of progesterone on TLR3, TLR4-triggered immune response

Study on role of paternal antigens-specific CD4+CD25+T regulatory cells during pregnancy

In vitro study of inhibitory effects of pregnancy-induced regulatory T cells on na?ve T cells prolifera-tion

Protective Effects of Interferon-tau Against Lipopolysaccharide-Induced Embryo Implantation Failure in Pregnant Mice

Progesterone Attenuates Brain Inflammatory Response and Inflammation-Induced Increase in Immature Myeloid Cells in a Mouse Model

Progesterone Regulates Mouse Dendritic Cells Differentiation and Maturation

Administration of Exogenous Progesterone Protects Against <i>Brucella abortus</i> Infection-Induced Inflammation in Pregnant Mice

Pregnancy Induces an Immunological Memory Characterized by Maternal Immune Alterations Through Specific Genes Methylation

Progesterone Increases Systemic and Local Uterine Proportions of CD4+CD25+ Treg Cells During Midterm Pregnancy in Mice.

Impact of progesterone on innate immunity and cell death after influenza A virus H1N1 2009 infection of lung and placental cells in vitro

Progesterone is Involved in the Maturation of Murine Spleen CD11c-positive Dendritic Cells

Estradiol Attenuates the Severity of Primary Toxoplasma gondii Infection-Induced Adverse Pregnancy Outcomes Through the Regulation of Tregs in a Dose-Dependent Manner.

Progesterone-mediated remodeling of the maternal-fetal interface by a PGRMC1-dependent mechanism

A Change in Antigen Presentation Ability of Spleen Macrophage from Balb/c Mouse During Late Pregnancy

Abstract 3971: Progesterone impacts regulatory T cell activity to promote immunosuppression in the mammary gland

Pregnancy Estrogen Drives the Changes of T-lymphocyte Subsets and Cytokines and Prolongs the Survival of H-Y Skin Graft in Murine Model.

Regulation of progesterone on interleukins and TNF-α expression of murine CD11c positive splenic dendritic cells

Modulation of innate immune response to viruses including SARS-CoV-2 by progesterone

Abstract 6877: Progesterone promotes immunosuppression in the murine mammary gland by causing T cell death